search
Back to results

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Primary Purpose

Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor

Status
Withdrawn
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
177Lu-DOTATOC
Sponsored by
British Columbia Cancer Agency
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuroendocrine Tumors

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Able to provide written informed consent
  • Age greater than or equal to 19 years
  • Biopsy-proven, well-differentiated grade 1 - 3 NET
  • Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma, VIPoma, etc.), functioning and non-functioning
  • Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma)
  • Pulmonary NET, functioning and non-functioning
  • Easter Cooperative Oncology Group (ECOG) ≤ 2
  • Ki67 ≤ 55%
  • Progressive disease demonstrated by RECIST 1.1 criteria within the 6 months preceding the study.
  • Patients with other evidence of progressive disease that is not demonstrated on CT (like rising biomarkers) may be included, at the discretion of the Tumour Review Board.
  • If response to other treatments is considered adequate according to other criteria, the Tumour Review Board may consider excluding the patient from participation in the study.
  • Tumour Review Board confirmation of suitability to proceed to PRRT treatment and enrollment in this trial.
  • Positive PET SSR imaging (Krenning score 2 or higher) in previous 6 months (68Ga-DOTATOC, 68Ga-DOTATATE, 18F-AmBF3-TATE). If PET SSR imaging is not available 111In-penetreotide scintigraphy (Octreotide scan) is acceptable.
  • Adequate laboratory parameters within two weeks of enrollment

  • Kidneys

    • Serum creatinine ≤ 150 µmol/L
    • GFR ≥ 40 ml/min (using plasma clearance values)

  • Marrow

    • Hemoglobin ≥ 80 g/L
    • WBC ≥ 2 x 109/L
    • Platelets ≥ 75 x 109/L
    • Liver
  • Total bilirubin ≤ 3 x upper limit of normal (ULN)
  • ALT ≤ 3 x ULN or ≤ 5 x ULN if liver metastasis
  • Alkaline phosphatase ≤ 3 x ULN or ≤ 5 x ULN if liver metastasis
  • Subject's ability to comply with scheduled visits, treatment plans, laboratory tests, imaging tests, and other procedures required as detailed in the protocol.

Exclusion Criteria:

  • Women and men of childbearing potential Procreation

    • Women: pregnancy test done before enrollment before each treatment cycle. And subject must use adequate contraception for the duration of therapy, be surgically sterile, or post-menopausal.
    • Men: must be surgically sterile or use adequate contraception for the duration of the therapy.
  • Patient with another non-cutaneous (excluding melanoma) active cancer requiring therapeutic intervention.
  • Curative medical or surgical treatment, local liver embolization, or debulking are appropriate options.
  • Life expectancy is less than 12 weeks.
  • Radiotherapy to target lesions ≤ 12 weeks ago or to more than 25% of bone marrow.
  • PRRT at any time prior to randomization in this study.
  • Systemic therapy (chemotherapy) within 4 weeks of PRRT and other locoregional therapies (radioisotope, embolization) within 12 weeks prior to enrollment. Ongoing use of somatostatin analogs for control of symptoms is allowed.
  • Known brain metastases (unless treated and stable for more than 3 months).
  • Co-morbidities that could, in the opinion of the PI, interfere with safe delivery of PRRT (like urinary incontinence, psychiatric illness), uncontrolled congestive heart failure (NYHA II, III, IV)
  • Breastfeeding (if patients elect to discontinue breast feeding, they can participate in the trial).

Sites / Locations

  • BC Cancer

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard PRRT

Personalized PRRT

Arm Description

For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.

For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.

Outcomes

Primary Outcome Measures

Determine whether personalized 177Lu-DOTATOC PRRT reduces adverse events (AE).
Frequency of AEs, will be compared between the two treatment arms.
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with RECIST criteria.
PFS will be determined by RECIST1.1 criteria on serial CT, and analysed independently. The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with ITMO criteria.
PFS will be determined by biochemical criteria (ITMO) on serial CT, and analysed independently. The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.
PFS will be determined by Choi criteria on serial CT, and analysed independently. The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.

Secondary Outcome Measures

Determine response rate of both treatment arms with RECIST1.1 criteria
Response rate as determined by structural criteria RECIST1.1
Determine response rate of both treatment arms with Choi criteria
Response rate as determined by structural criteria Choi.
Determine response rate of both treatment arms with ITMO criteria
Response rate as determined by structural criteria biochemical markers (ITMO criteria) (chromogranin A, 24h urinary HIAA).
Quality of life (QoL) questionnaire scores (EORTC QLQ30) will be compared between the two treatment arms
For QoL questionnaire scores (EORTC QLQ30) before, during, and after treatment
Quality of life (QoL) questionnaire scores (EORTC GINET21) will be compared between the two treatment arms
For QoL questionnaire scores (EORTC GINET21) before, during, and after treatment
Quality of life (QoL) questionnaire scores (EQ-5D) will be compared between the two treatment arms
For QoL questionnaire scores (EQ-5D) before, during, and after treatment
Correlation of QoL scores (EORTC QLQ30) to ctDNA
To assess correlation of QoL scores (EORTC QLQ30) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
Correlation of QoL scores (EORTC GINET21) to ctDNA
To assess correlation of QoL scores (EORTC GINET21) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
Correlation of QoL scores (EQ-5D) to ctDNA
To assess correlation of QoL scores (EQ-5D) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation

Full Information

First Posted
April 28, 2021
Last Updated
February 17, 2023
Sponsor
British Columbia Cancer Agency
search

1. Study Identification

Unique Protocol Identification Number
NCT04915144
Brief Title
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
Official Title
A Prospective Randomized Study of the Efficacy and Safety of 177Lu-DOTATOC With Either Standard or Personalized Dosing for the Treatment of Patients With Somatostatin Receptor Positive NETs
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Investigator decision
Study Start Date
January 15, 2023 (Anticipated)
Primary Completion Date
December 31, 2027 (Anticipated)
Study Completion Date
December 31, 2031 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
British Columbia Cancer Agency

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires. Subjects will be followed for 5 years or until they have progression and are switched to another systemic treatment (not including treatment with somatostatin analogues).
Detailed Description
Overall, 200 subjects will be randomized (1:1 randomization ratio) to receive standard injected activities of 177Lu-DOTATOC PRRT or personalized injection of 177Lu-DOTATOC PRRT. Randomization will be stratified for grade and primary location. Screening Phase: Subjects will be screened against the inclusion and exclusion criteria. Screening by SSR imaging will be completed to determine expression of SSR and feasibility of treatment by PRRT. Once eligibility has been confirmed they will be randomized. Subjects will undergo a physical exam, complete a medical history questionnaire, quality of life questionnaires, blood work, and a diagnostic CT. Treatment Phase: During the treatment phase, subjects will undergo 4 cycles of treatment. Each treatment cycle will be followed by 2 dosimetry SPECT/CT scans on day 1 (18 - 32 hours after treatment administration) and day 2 (64 - 80h after treatment administration) After cycle 3 quality of life questionnaires will be completed again. Follow up Phase: At the end of treatment or after discontinuation of any cause, subjects will be followed for 5 years to continue data collection for the other objectives. Objective tumour response will be assessed every 6 months by diagnostic CT according to the RECIST 1.1 criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Vipoma, Insulinoma, Gastrinoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
This is a prospective randomized phase II study two-arm study of efficacy and safety of 177Lu-DOTATOC for treatment of patients with NETs who are referred to BC Cancer - Vancouver for treatment of progressive tumours.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard PRRT
Arm Type
Active Comparator
Arm Description
For standard PRRT 177Lu-DOTATOC therapy, the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.
Arm Title
Personalized PRRT
Arm Type
Experimental
Arm Description
For 177Lu-DOTATOC therapy, for the first cycle the administered activity will be 7.4 GBq ± 10% as an intravenous infusion over a time of 10 to 30 minutes.Subsequent cycles will be adjusted based on dosimetry calculations.
Intervention Type
Drug
Intervention Name(s)
177Lu-DOTATOC
Intervention Description
Subjects will receive 177Lu-DOTATOC PRRT treatment over 4 cycles, each cycle occurs every 8 weeks.
Primary Outcome Measure Information:
Title
Determine whether personalized 177Lu-DOTATOC PRRT reduces adverse events (AE).
Description
Frequency of AEs, will be compared between the two treatment arms.
Time Frame
8 months
Title
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with RECIST criteria.
Description
PFS will be determined by RECIST1.1 criteria on serial CT, and analysed independently. The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
Time Frame
12 months
Title
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with ITMO criteria.
Description
PFS will be determined by biochemical criteria (ITMO) on serial CT, and analysed independently. The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
Time Frame
12 months
Title
Compare the 12-month progression-free survival (PFS) of subjects receiving personalized or standard injected activity PRRT with Choi criteria.
Description
PFS will be determined by Choi criteria on serial CT, and analysed independently. The 12-month PFS will be evaluated by univariate analysis but different criteria for determination of PFS will be compared.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Determine response rate of both treatment arms with RECIST1.1 criteria
Description
Response rate as determined by structural criteria RECIST1.1
Time Frame
4 months
Title
Determine response rate of both treatment arms with Choi criteria
Description
Response rate as determined by structural criteria Choi.
Time Frame
4 months
Title
Determine response rate of both treatment arms with ITMO criteria
Description
Response rate as determined by structural criteria biochemical markers (ITMO criteria) (chromogranin A, 24h urinary HIAA).
Time Frame
4 months
Title
Quality of life (QoL) questionnaire scores (EORTC QLQ30) will be compared between the two treatment arms
Description
For QoL questionnaire scores (EORTC QLQ30) before, during, and after treatment
Time Frame
8 months
Title
Quality of life (QoL) questionnaire scores (EORTC GINET21) will be compared between the two treatment arms
Description
For QoL questionnaire scores (EORTC GINET21) before, during, and after treatment
Time Frame
8 months
Title
Quality of life (QoL) questionnaire scores (EQ-5D) will be compared between the two treatment arms
Description
For QoL questionnaire scores (EQ-5D) before, during, and after treatment
Time Frame
8 months
Title
Correlation of QoL scores (EORTC QLQ30) to ctDNA
Description
To assess correlation of QoL scores (EORTC QLQ30) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
Time Frame
8 months
Title
Correlation of QoL scores (EORTC GINET21) to ctDNA
Description
To assess correlation of QoL scores (EORTC GINET21) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
Time Frame
8 months
Title
Correlation of QoL scores (EQ-5D) to ctDNA
Description
To assess correlation of QoL scores (EQ-5D) to ctDNA allele frequency change from pre-treatment to on-treatment, using spearman correlation
Time Frame
8 months
Other Pre-specified Outcome Measures:
Title
PFS and QoL scores to ctDNA levels
Description
To assess correlation of PFS and QoL scores (EORTC QLQ30) to ctDNA levels (ctDNA allele frequency change from pre-treatment to on-treatment), the following tests will be used, Spearman correlation for quality of life and Kaplan- Meier curves stratified at a median for PFS.
Time Frame
8 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Able to provide written informed consent Age greater than or equal to 19 years Biopsy-proven, well-differentiated grade 1 - 3 NET Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma, VIPoma, etc.), functioning and non-functioning Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma) Pulmonary NET, functioning and non-functioning Easter Cooperative Oncology Group (ECOG) ≤ 2 Ki67 ≤ 55% Progressive disease demonstrated by RECIST 1.1 criteria within the 6 months preceding the study. Patients with other evidence of progressive disease that is not demonstrated on CT (like rising biomarkers) may be included, at the discretion of the Tumour Review Board. If response to other treatments is considered adequate according to other criteria, the Tumour Review Board may consider excluding the patient from participation in the study. Tumour Review Board confirmation of suitability to proceed to PRRT treatment and enrollment in this trial. Positive PET SSR imaging (Krenning score 2 or higher) in previous 6 months (68Ga-DOTATOC, 68Ga-DOTATATE, 18F-AmBF3-TATE). If PET SSR imaging is not available 111In-penetreotide scintigraphy (Octreotide scan) is acceptable. Adequate laboratory parameters within two weeks of enrollment Kidneys Serum creatinine ≤ 150 µmol/L GFR ≥ 40 ml/min (using plasma clearance values) Marrow Hemoglobin ≥ 80 g/L WBC ≥ 2 x 109/L Platelets ≥ 75 x 109/L Liver Total bilirubin ≤ 3 x upper limit of normal (ULN) ALT ≤ 3 x ULN or ≤ 5 x ULN if liver metastasis Alkaline phosphatase ≤ 3 x ULN or ≤ 5 x ULN if liver metastasis Subject's ability to comply with scheduled visits, treatment plans, laboratory tests, imaging tests, and other procedures required as detailed in the protocol. Exclusion Criteria: Women and men of childbearing potential Procreation Women: pregnancy test done before enrollment before each treatment cycle. And subject must use adequate contraception for the duration of therapy, be surgically sterile, or post-menopausal. Men: must be surgically sterile or use adequate contraception for the duration of the therapy. Patient with another non-cutaneous (excluding melanoma) active cancer requiring therapeutic intervention. Curative medical or surgical treatment, local liver embolization, or debulking are appropriate options. Life expectancy is less than 12 weeks. Radiotherapy to target lesions ≤ 12 weeks ago or to more than 25% of bone marrow. PRRT at any time prior to randomization in this study. Systemic therapy (chemotherapy) within 4 weeks of PRRT and other locoregional therapies (radioisotope, embolization) within 12 weeks prior to enrollment. Ongoing use of somatostatin analogs for control of symptoms is allowed. Known brain metastases (unless treated and stable for more than 3 months). Co-morbidities that could, in the opinion of the PI, interfere with safe delivery of PRRT (like urinary incontinence, psychiatric illness), uncontrolled congestive heart failure (NYHA II, III, IV) Breastfeeding (if patients elect to discontinue breast feeding, they can participate in the trial).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francois Benard, MD
Organizational Affiliation
BC Cancer
Official's Role
Principal Investigator
Facility Information:
Facility Name
BC Cancer
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E6
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

We'll reach out to this number within 24 hrs